ARVINAS, INC. Research and Development Expense
ARVINAS, INC. (ARVN) reported Research and Development Expense of $52.60 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-04
- ARVINAS, INC. research and development expense for the quarter ending 2026-06-30 was $52.60M, a 23.32% decline year-over-year.
- ARVINAS, INC. research and development expense for the quarter ending 2026-03-31 was $60.30M, a 33.59% decline year-over-year.
- ARVINAS, INC. research and development expense for the quarter ending 2025-12-31 was $61.10M, a 26.65% decline year-over-year.
- ARVINAS, INC. research and development expense for the quarter ending 2025-09-30 was $64.70M, a 25.55% decline year-over-year.
- ARVINAS, INC. research and development expense for fiscal 2025 was $285.20M, a 18.09% decline from fiscal 2024.
- ARVINAS, INC. research and development expense for fiscal 2024 was $348.20M, a 8.30% decline from fiscal 2023.
- ARVINAS, INC. research and development expense for fiscal 2023 was $379.70M, a 20.54% increase from fiscal 2022.
- ARVINAS, INC. research and development expense for fiscal 2022 was $315.00M, a 74.61% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 3 month as first filed | Research and Development Expense 6 month | Research and Development Expense 6 month as first filed | Research and Development Expense 9 month | Research and Development Expense 9 month as first filed | Research and Development Expense 12 month | Research and Development Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $52.60M 10-Q · filed 2026-08-04 | $113.00M 10-Q · filed 2026-08-04 | $174.00M derived: sum of 3 quarters · filed 2026-08-04 | $238.70M derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2026-03-31 | $60.30M 10-Q · filed 2026-05-11 | $121.40M derived: sum of 2 quarters · filed 2026-05-11 | $186.10M derived: sum of 3 quarters · filed 2026-05-11 | $254.70M derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2025-12-31 | $61.10M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $125.80M derived: sum of 2 quarters · filed 2026-02-24 | $194.40M derived: sum of 3 quarters · filed 2026-08-04 | $285.20M 10-K · filed 2026-02-24 | ||||
| 2025-09-30 | $64.70M 10-Q · filed 2025-11-05 | $133.30M derived: sum of 2 quarters · filed 2026-08-04 | $224.10M 10-Q · filed 2025-11-05 | $307.40M derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2025-06-30 | $68.60M 10-Q · filed 2026-08-04 | $159.40M 10-Q · filed 2026-08-04 | $242.70M derived: sum of 3 quarters · filed 2026-08-04 | $329.60M derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2025-03-31 | $90.80M 10-Q · filed 2026-05-11 | $174.10M derived: sum of 2 quarters · filed 2026-05-11 | $261.00M derived: sum of 3 quarters · filed 2026-05-11 | $354.70M derived: sum of 4 quarters · filed 2026-05-11 | ||||
| 2024-12-31 | $83.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $170.20M derived: sum of 2 quarters · filed 2026-02-24 | $263.90M derived: sum of 3 quarters · filed 2026-02-24 | $348.20M 10-K · filed 2026-02-24 | ||||
| 2024-09-30 | $86.90M 10-Q · filed 2025-11-05 | $180.60M derived: sum of 2 quarters · filed 2025-11-05 | $264.90M 10-Q · filed 2025-11-05 | $360.10M derived: sum of 4 quarters · filed 2026-02-24 | ||||
| 2024-06-30 | $93.70M 10-Q · filed 2025-08-06 | $178.00M 10-Q · filed 2025-08-06 | $273.20M derived: sum of 3 quarters · filed 2026-02-24 | $359.10M derived: sum of 4 quarters · filed 2026-02-24 | ||||
| 2024-03-31 | $84.30M 10-Q · filed 2025-05-01 | $179.50M derived: sum of 2 quarters · filed 2026-02-24 | $265.40M derived: sum of 3 quarters · filed 2026-02-24 | $368.80M derived: sum of 4 quarters · filed 2026-02-24 | ||||
| 2023-12-31 | $95.20M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $181.10M derived: sum of 2 quarters · filed 2026-02-24 | $284.50M derived: sum of 3 quarters · filed 2026-02-24 | $379.70M 10-K · filed 2026-02-24 | ||||
| 2023-09-30 | $85.90M 10-Q · filed 2024-10-30 | $189.30M derived: sum of 2 quarters · filed 2024-10-30 | $284.50M 10-Q · filed 2024-10-30 | $382.90M derived: sum of 4 quarters · filed 2025-02-11 | ||||
| 2023-06-30 | $103.40M 10-Q · filed 2024-07-30 | $198.60M 10-Q · filed 2024-07-30 | $297.00M derived: sum of 3 quarters · filed 2025-02-11 | $374.50M derived: sum of 4 quarters · filed 2025-02-11 | ||||
| 2023-03-31 | $95.30M 10-Q · filed 2024-05-07 | $193.60M derived: sum of 2 quarters · filed 2025-02-11 | $271.10M derived: sum of 3 quarters · filed 2025-02-11 | $346.40M derived: sum of 4 quarters · filed 2025-02-11 | ||||
| 2022-12-31 | $98.30M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-11 | $175.80M derived: sum of 2 quarters · filed 2025-02-11 | $251.10M derived: sum of 3 quarters · filed 2025-02-11 | $315.00M 10-K · filed 2025-02-11 | ||||
| 2022-09-30 | $77.50M 10-Q · filed 2023-11-07 | $152.80M derived: sum of 2 quarters · filed 2023-11-07 | $216.70M 10-Q · filed 2023-11-07 | $278.70M derived: sum of 4 quarters · filed 2024-02-27 | ||||
| 2022-06-30 | $75.30M 10-Q · filed 2023-08-08 | $139.20M 10-Q · filed 2023-08-08 | $201.20M derived: sum of 3 quarters · filed 2024-02-27 | $241.80M derived: sum of 4 quarters · filed 2024-02-27 | ||||
| 2022-03-31 | $64.00M 10-Q · filed 2023-05-05 | $125.90M derived: sum of 2 quarters · filed 2024-02-27 | $166.50M derived: sum of 3 quarters · filed 2024-02-27 | $209.50M derived: sum of 4 quarters · filed 2024-02-27 | ||||
| 2021-12-31 | $61.90M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $102.50M derived: sum of 2 quarters · filed 2024-02-27 | $145.50M derived: sum of 3 quarters · filed 2024-02-27 | $180.40M 10-K · filed 2024-02-27 | ||||
| 2021-09-30 | $40.60M 10-Q · filed 2022-11-09 | $40.60M 10-Q · filed 2021-11-03 | $83.60M derived: sum of 2 quarters · filed 2022-11-09 | $118.50M 10-Q · filed 2022-11-09 | $118.48M 10-Q · filed 2021-11-03 | $151.74M derived: sum of 4 quarters · filed 2023-02-23 | ||
| 2021-06-30 | $43.00M 10-Q · filed 2022-08-04 | $43.01M 10-Q · filed 2021-08-05 | $77.90M 10-Q · filed 2022-08-04 | $77.88M 10-Q · filed 2021-08-05 | $111.14M derived: sum of 3 quarters · filed 2023-02-23 | $141.16M derived: sum of 4 quarters · filed 2023-02-23 | ||
| 2021-03-31 | $34.90M 10-Q · filed 2022-05-05 | $34.87M 10-Q · filed 2021-05-04 | $68.14M derived: sum of 2 quarters · filed 2023-02-23 | $98.16M derived: sum of 3 quarters · filed 2023-02-23 | $121.57M derived: sum of 4 quarters · filed 2023-02-23 | |||
| 2020-12-31 | $33.24M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $63.26M derived: sum of 2 quarters · filed 2023-02-23 | $86.67M derived: sum of 3 quarters · filed 2023-02-23 | $108.40M 10-K · filed 2023-02-23 | $108.36M 10-K · filed 2021-03-01 | |||
| 2020-09-30 | $30.01M 10-Q · filed 2021-11-03 | $53.43M derived: sum of 2 quarters · filed 2021-11-03 | $75.16M 10-Q · filed 2021-11-03 | $95.57M derived: sum of 4 quarters · filed 2021-11-03 | ||||
| 2020-06-30 | $23.42M 10-Q · filed 2021-08-05 | $45.14M 10-Q · filed 2021-08-05 | $65.56M derived: sum of 3 quarters · filed 2021-08-05 | $82.15M derived: sum of 4 quarters · filed 2021-08-05 | ||||
| 2020-03-31 | $21.73M 10-Q · filed 2021-05-04 | $42.14M derived: sum of 2 quarters · filed 2021-05-04 | $58.73M derived: sum of 3 quarters · filed 2021-05-04 | $74.73M derived: sum of 4 quarters · filed 2021-05-04 | ||||
| 2019-12-31 | $20.41M 10-K · filed 2020-03-16 | $37.00M derived: sum of 2 quarters · filed 2020-11-05 | $53.00M derived: sum of 3 quarters · filed 2020-11-05 | $67.20M 10-K · filed 2022-02-28 | $67.19M 10-K · filed 2020-03-16 | |||
| 2019-09-30 | $16.59M 10-Q · filed 2020-11-05 | $32.59M derived: sum of 2 quarters · filed 2020-11-05 | $46.78M 10-Q · filed 2020-11-05 | $61.34M derived: sum of 4 quarters · filed 2020-11-05 | ||||
| 2019-06-30 | $16.00M 10-Q · filed 2020-08-04 | $30.19M 10-Q · filed 2020-08-04 | $44.75M derived: sum of 3 quarters · filed 2020-08-04 | $57.90M derived: sum of 4 quarters · filed 2020-08-04 | ||||
| 2019-03-31 | $14.19M 10-Q · filed 2020-04-28 | $28.75M derived: sum of 2 quarters · filed 2020-04-28 | $41.90M derived: sum of 3 quarters · filed 2020-04-28 | $52.24M derived: sum of 4 quarters · filed 2020-04-28 | ||||
| 2018-12-31 | $14.56M 10-K · filed 2020-03-16 | $27.71M derived: sum of 2 quarters · filed 2020-03-16 | $38.05M derived: sum of 3 quarters · filed 2020-03-16 | $45.19M 10-K · filed 2021-03-01 | ||||
| 2018-09-30 | $13.15M 10-K · filed 2020-03-16 | $23.49M derived: sum of 2 quarters · filed 2020-03-16 | $30.63M 10-Q · filed 2019-11-04 | $37.32M derived: sum of 4 quarters · filed 2020-03-16 | ||||
| 2018-06-30 | $10.34M 10-K · filed 2020-03-16 | $17.48M 10-Q · filed 2019-08-05 | $24.17M derived: sum of 3 quarters · filed 2020-03-16 | $31.39M derived: sum of 4 quarters · filed 2020-03-16 | ||||
| 2018-03-31 | $7.14M 10-K · filed 2020-03-16 | $13.83M derived: sum of 2 quarters · filed 2020-03-16 | $21.06M derived: sum of 3 quarters · filed 2020-03-16 | $28.88M derived: sum of 4 quarters · filed 2020-03-16 | ||||
| 2017-12-31 | $6.69M 10-K · filed 2019-03-26 | $13.91M derived: sum of 2 quarters · filed 2019-03-26 | $21.74M derived: sum of 3 quarters · filed 2019-03-26 | $28.79M 10-K · filed 2019-03-26 | ||||
| 2017-09-30 | $7.22M 10-K · filed 2019-03-26 | $15.05M derived: sum of 2 quarters · filed 2019-03-26 | $22.10M 10-Q · filed 2018-11-14 | |||||
| 2017-06-30 | $7.82M 10-K · filed 2019-03-26 | $14.88M derived: sum of 2 quarters · filed 2019-03-26 | ||||||
| 2017-03-31 | $7.06M 10-K · filed 2019-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 |